A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Desmetramadol (Primary) ; Tramadol
- Indications Pain
- Focus Therapeutic Use
- Sponsors Syntrix Biosystems
- 26 Dec 2017 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 Planned End Date changed from 31 Jan 2018 to 22 Dec 2017.
- 14 Dec 2017 Planned primary completion date changed from 28 Jan 2018 to 15 Dec 2017.